Brief: Statera Biopharma Submits Phase 1 Clinical Trial Protocol To FDA For Investigational Treatment Of Long-Haul Covid-19
02/03/2022 12:42
March 2 (Reuters) - Statera Biopharma Inc STAB.O :
* STATERA BIOPHARMA SUBMITS PHASE 1 CLINICAL TRIAL PROTOCOL
TO FDA
FOR INVESTIGATIONAL TREATMENT OF LONG-HAUL COVID-19
Source text for Eikon: ID:nGNX2S18sY
Further company coverage: STAB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Statera Biopharma
See all news20/20 Biolabs jumps on Ebola, hantavirus testing plans
Tivic Health Systems rises after deal for late-stage immunotherapy drug
Brief: Tivic Health Acquires Exclusive Worldwide Rights To Phase III TLR5 Agonist
Brief: Statera Biopharma Inc Quarterly Loss Per Share $0.20
Brief: Statera Biopharma Inc - On October 12, 2022, Co Entered A Binding Memorandum Of Understanding (“MoU”) With Holobeam Technologies, Inc